Compare JPMorgan Chase & Co (JPM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Chase & Co trades at $339.1 (market cap $900.78B), while Regeneron Pharmaceuticals Inc trades at $672.4 (market cap $70.47B). The key difference: JPMorgan Chase & Co is far larger — about 12.8× Regeneron Pharmaceuticals Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| JPM | REGN | |
|---|---|---|
Market Cap | $900.78B | $70.47B |
Volume | 10,479,943 | — |
Sector | Financials | Health |
52-Week High | $346.91 | $812.27 |
52-Week Low | $282.84 | $545.46 |
Dividend Yield | 1.77% | 0.56% |
Enterprise Value | — | $64.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase trades at $341.10, down 0.6% on the day, with a bullish technical signal from moving averages and support at $339. The company reported strong Q1 and Q2 2026 earnings beats, with revenue growth from $169.4B in 2024 to $181.8B in 2025. Analyst consensus is Moderate Buy with a $374 price target, representing 9.6% upside potential. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 earnings on April 14.
JPMorgan demonstrates solid fundamentals with consistent revenue growth and strong net income margins above 30%. The stock appears reasonably valued with a P/E of 14.6. Key risks include geopolitical tensions impacting banking operations and cybersecurity vulnerabilities from advanced AI systems. The bullish analyst sentiment and technical setup suggest potential for continued upside if earnings momentum persists.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
